Singular Genomics Systems Inc. (NASDAQ: OMIC) Stock Information | RedChip

Singular Genomics Systems Inc. (NASDAQ: OMIC) Listen to this Section


$6.91
-0.2810 ( -3.91% ) 0.9K

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Market Data


Open


$6.91

Previous close


$7.19

Volume


0.9K

Market cap


$16.40M

Day range


$6.92 - $7.19

52 week range


$6.78 - $19.80

Insider Ownership Transactions

Total Amount Purchased: -234,990.00 | $ -1,622,605.95

Date Type Amount Purchased Purchaser
2024-08-14 Sale -1906.00 Spaventa Andrew
2024-08-13 Sale -500.00 Meeter Dalen
2024-08-13 Sale -500.00 Glezer Eli N.
2024-08-13 Sale -250.00 Ghai Jyotsna
2024-06-18 Sale -7500.00 Glezer Eli N.
2024-06-18 Sale -14584.00 Spaventa Andrew
2024-06-18 Sale -6250.00 Meeter Dalen
2024-05-31 Sale -74000.00 BARKER DAVID L
2024-05-31 Sale -55500.00 Eisenberg Marcia
2024-05-31 Sale -74000.00 Ryan Jason

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Aug 14, 2024
4 Insider transactions 1 Aug 13, 2024
10-q Quarterly Reports 77 Aug 13, 2024
8-k 8K-related 13 Aug 13, 2024
4 Insider transactions 1 Aug 13, 2024
4 Insider transactions 1 Aug 13, 2024
8-k 8K-related 12 Aug 07, 2024
8-k 8K-related 13 Jul 15, 2024
8-k 8K-related 12 Jun 27, 2024
4 Insider transactions 1 Jun 18, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.